Addenda Capital Inc. Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Addenda Capital Inc. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.8% in the 4th quarter, HoldingsChannel reports. The fund owned 48,662 shares of the medical research company’s stock after purchasing an additional 3,507 shares during the period. Addenda Capital Inc.’s holdings in IQVIA were worth $9,563,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new position in IQVIA in the 3rd quarter valued at approximately $28,000. Itau Unibanco Holding S.A. bought a new stake in IQVIA during the 2nd quarter valued at $29,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.2 %

IQV stock opened at $197.25 on Tuesday. The company has a market capitalization of $35.80 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company’s 50 day moving average price is $200.09 and its two-hundred day moving average price is $221.39.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IQV. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Wednesday, December 11th. Leerink Partners restated an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.